• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    President and CEO White Marvin L converted options into 14 shares, increasing direct ownership by 34% to 55 units (SEC Form 4)

    3/4/25 4:33:33 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APVO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    White Marvin L

    (Last) (First) (Middle)
    2401 4TH AVENUE
    1,050

    (Street)
    SEATTLE WA 98121

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Aptevo Therapeutics Inc. [ APVO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President and CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    03/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/02/2025 M 8 A (1) 49 D
    Common Stock 03/03/2025 M 6 A (1) 55 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Unit (1) 03/02/2025 M 8 (2) (2) Common Stock 8 $0 8 D
    Restricted Stock Unit (1) 03/03/2025 M 6 (3) (3) Common Stock 6 $0 0 D
    Explanation of Responses:
    1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
    2. On March 3, 2023, the reporting person was granted 38,750 (24 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024.
    3. On June 7, 2022, the reporting person was granted 28,750 (18 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023.
    /s/ SoYoung Kwon, Attorney-In-Fact 03/04/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $APVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APVO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APVO
    SEC Filings

    See more
    • SEC Form 424B4 filed by Aptevo Therapeutics Inc.

      424B4 - Aptevo Therapeutics Inc. (0001671584) (Filer)

      6/20/25 9:00:22 AM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Aptevo Therapeutics Inc.

      EFFECT - Aptevo Therapeutics Inc. (0001671584) (Filer)

      6/20/25 12:15:21 AM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1MEF filed by Aptevo Therapeutics Inc.

      S-1MEF - Aptevo Therapeutics Inc. (0001671584) (Filer)

      6/18/25 2:30:31 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Aptevo Therapeutics with a new price target

      Roth Capital reiterated coverage of Aptevo Therapeutics with a rating of Buy and set a new price target of $50.00 from $64.00 previously

      5/28/21 8:33:45 AM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, GC, BD & Corp Affairs Kwon Soyoung converted options into 4 shares, increasing direct ownership by 19% to 25 units (SEC Form 4)

      4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

      3/4/25 4:36:04 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, COO Lamothe Jeffrey G. converted options into 5 shares, increasing direct ownership by 16% to 36 units (SEC Form 4)

      4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

      3/4/25 4:35:19 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO White Marvin L converted options into 14 shares, increasing direct ownership by 34% to 55 units (SEC Form 4)

      4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

      3/4/25 4:33:33 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

      Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design expertise SEATTLE, WA / ACCESSWIRE / January 15, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and present a talk,"Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," at the Cambridge Healthcare Institute's Pep Talk conference today.DetailsSession Title: Bi and Multispecific BiologicsTalk Title: Modular Multispecific

      1/15/25 8:00:00 AM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

      SEATTLE, WASHINGTON / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common s

      12/12/24 12:50:00 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

      Two of three patients achieved both complete remission and MRD-negative statusHigh response rates observed in earlier studies continue in ongoing mipletamig trialCohort 2 enrollment commencing SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced 100% of patients achieved remission* within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial, including two patients who experienced complete remission with minimal residual d

      12/12/24 9:00:00 AM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care